Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus la-5
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravaginal, Topical, Rectal
01
Overview
Lactobacillus acidophilus LA-5 is a specific, well-documented probiotic strain of the bacterium Lactobacillus acidophilus. It was developed by the company Chr. Hansen (now part of Novonesis) and has been used in food products and dietary supplements since 1979. [1, 3] The strain is often studied and used in combination with Bifidobacterium animalis subsp. lactis BB-12. [1] Research indicates that L. acidophilus LA-5 has immunomodulatory properties. In studies on peripheral blood mononuclear cells from patients with ulcerative colitis, it was shown to augment the secretion of both pro-inflammatory cytokines (TNF-α, IFN-γ) and anti-inflammatory cytokines (IL-10, TGF-β). Another study in an experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis found that LA-5 supplementation improved disease severity by modulating the pentose phosphate pathway and activating the Nrf2 antioxidant pathway. It is commercially available and marketed for supporting digestive and women's health. [3, 6]
- Brand names
- LA-5LA5LA 5
- Other names
- L. acidophilus LA-5
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on lactobacillus acidophilus la-5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus la-5.